drugset / Trial / NCT03058757

The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation

NCT03058757

Phase 2 Completed 71 enrolled National Cancer Center, Korea
RandomizedParallel-groupOpen-labelPrevention

Summary

The aim of this study is to evaluate the effectiveness and safety of neoadjuvant intravesical mitomycin-C instillation in non-muscle invasive bladder cancer patients

Timeline

Start
2017-02-01
Primary completion
2021-02-18
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitomycin C Other / unclassified 20 ml Other
Subject Mitomycin C Other / unclassified 40 mg Other